Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

News Conference News AHA 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure ANDES

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

News Conference News EACTS 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

Yael L. Maxwell

October 13, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

News Conference News ESOC 2025

High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

May 29, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

News Conference News CRT 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

March 10, 2025

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

News Conference News ESC 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

September 06, 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

News Conference News ESC 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

August 31, 2024

Leaks After LAAO Do Matter, Experts Agree

News Conference News NY Valves 2024

Leaks After LAAO Do Matter, Experts Agree

June 10, 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

EHRA, Others Update Consensus on Catheter and Surgical Ablation of AF

News Conference News EHRA 2024

EHRA, Others Update Consensus on Catheter and Surgical Ablation of AF

April 08, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

ELAN: Early DOACs Safe, May Help After Ischemic Stroke in AF Patients

News Conference News ESOC 2023

ELAN: Early DOACs Safe, May Help After Ischemic Stroke in AF Patients

May 24, 2023

BEST-CLI: Experts at ISET Look to Bridge Research Results and Practice

News Conference News ISET 2023

BEST-CLI: Experts at ISET Look to Bridge Research Results and Practice

January 25, 2023

FLASH: More Data to Support Mechanical Thrombectomy in PE

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

September 18, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

News Conference News HRS 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

April 29, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.